Investors looking to anchor their portfolio with an all-around solid business might begin with one of these three stocks.
Tesla is an obvious choice, but one small-cap company plans to roll out an impressive new product lineup this year.
A down-on-its-luck fertilizer company and an exceptionally diversified biotech are solid investments for 2019.
Goldcorp announced it has agreed to be acquired by Newmont Mining in a deal that would create the world's largest gold producer.
The fuel cell pioneer struggled once again in 2018. What can investors expect in the year ahead?
The renewable energy leader, whose investments in wind and solar assets began paying off in 2018, is trading at a deep discount.
In a year characterized by market turmoil, investors found refuge in the steady and predictable DNA sequencing king.
The biopharma delivered the goods with its drug pipeline, scored marketing approval for its lead drug candidate, and agreed to be acquired for $8 billion.
In 2018, ethanol selling prices hit their lowest annual average since 2002, years before federally mandated fuel blending became law.
The company's two segments, agricultural solutions and lithium, turned in a strong performance, but concerns over the health of those two industries weighed on shares.
Increased costs from new global tariffs and higher raw-material prices weighed on operations throughout the year.
A short seller report knocked shares down in the beginning of last year. They never recovered.
The consumer lawn and garden portfolio was held back by a lingering winter, while the high-growth hydroponics segment encountered headwinds.
It was a trying year for many gold miners, but especially those with production problems.
An insatiable appetite for lithium stocks pushed valuations skyward in 2017, but the industry took a breather last year. The growth opportunities are still undeniable.
The gene-editing pioneer was an easy target during the end-of-the-year market sell-off.
The gene-editing pioneer surprised investors with the departure of its CFO, but there doesn't seem to be any cause for alarm.
The three gene-editing pioneers had mixed results last year, but each has big plans for the year ahead.
The tiny pharma company splashed onto the radar of investors this week with great trial results, but a maturing drug pipeline has one inescapable downside.
A volatile stock market dished out an extra dose of punishment to riskier assets, including these three small-cap pharma companies.